

**Funded Expressions of Interest  
1 July 2011 to 31 October 2012**

Associate Professor Michael **Beard**, University of Adelaide. 'Phase II of Laboratory-Based Platforms To Manage Patients Who Develop Antiviral Drug-Resistance To Direct-Acting Antiviral Agents (DAAs)'.

Dr. Till **Böcking**, University of New South Wales. 'Targeting HIV uncoating as an antiretroviral therapy'.

Dr. Rowena **Bull**, University of New South Wales. 'HCV founder viruses guide vaccine development'.

Associate Professor Melissa **Churchill**, Burnet Institute. 'Quantitative, real-time HIV neutralisation assay'.

Dr. Fasseli **Coulibaly**, Monash University. 'Immunogenicity study of HIV Env MicroCubes'.

Professor Tony **Cunningham**, Westmead Millennium Institute for Medical Research. 'TLR2 agonist - HIV peptide induction of the Th17 responses: A new immunotherapeutic and vaccine strategy?'

Associate Professor Mark **Gorrell**, University of Sydney. 'Novel outcome predictors in HCV post-liver transplant'.

Associate Professor Paul **Gorry**, Burnet Institute. 'Development and preclinical testing of novel HIV inhibitors with specific activity against viruses with CCR5-antagonistic resistance'.

Professor Eric **Gowans**, University of Adelaide. 'Development of a cytolytic HCV vaccine and a novel challenge model to test efficacy'.

Professor David **Jans**, Monash University. 'Nuclear Transport inhibitors as HIV anti-virals'.

Dr. Li **Peng**, SA Pathology. 'Designer antigens for production of broadly neutralizing antibodies (bN ABs against HIV)'.

Dr. Margaret **Littlejohn**, Victorian Infectious Diseases Reference Laboratory. 'Molecular Epidemiology of Hepatitis B in Indigenous Australian Populations'.

Dr. Fabio **Luciani**, University of New South Wales. 'Molecular epidemiology and social network analysis to track HCV transmission in high-risk communities: the case of injecting drug users in correction centres'.

Associate Professor Hans **Netter**, Monash University. 'Immunogenicity of virus-like particles containing HIV-1 neutralising epitopes and determination of the quality of the immune response'.

Dr. Clovis **Palmer**, Burnet Institute. 'Development of Bioelectronic Recognition Assays for immune monitoring during HIV infection'.

Professor Geoffrey **Pietersz**, Burnet Institute. 'Targeted activation of latently infected cells: a novel strategy towards HIV cure'.

Associate Professor Damian **Purcell**, University of Melbourne. 'Blocking TAT expression during HIV-1 viral latency'.

Professor Ron **Quinn**, Griffith University. 'Identification of novel HIV inhibitors via Fourier Transform Mass Spectrometry'.

Dr. Charani **Ranasinghe**, Australian National University. 'Design an effective poxvirus based vaccine for HIV-1 by modulating immune cell milieu using an IL-10 antagonist'.

Dr. Claire **Ryan**, Burnet Institute. 'Characterisation of novel CCR5 genotypes influencing the emerging and unique HIV-1 epidemic in Papua New Guinea'.

Associate Professor Joe Sasadeusz, Victorian Infectious Diseases Service, Royal Melbourne Hospital. 'The innate immunological determinants of spontaneous clearance in HIV-positive men who have sex with men acutely infected with Hepatitis C'.